about
AcromegalyNeed for improved monitoring in patients with acromegalyImpaired Pituitary Axes Following Traumatic Brain InjuryMeta-analysis on the effects of octreotide on tumor mass in acromegalyFactors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly.Thyroid nodules in acromegaly: The role of elastography.Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.Pegvisomant in acromegaly: an update.Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects.Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Management of acromegaly in Latin America: expert panel recommendationsSerum proteome changes in acromegalic patients following transsphenoidal surgery: novel biomarkers of disease activity.Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable?Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineTumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly.Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of DiseaseHealth Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life.Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients.Efficacy and complications of neurosurgical treatment of acromegaly.PPAR-gamma receptor ligands: novel therapy for pituitary adenomas.Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormone-secreting macroadenomaLong-term outcome and mortality after transsphenoidal adenomectomy for acromegaly.Primary medical therapy for acromegaly.Modern treatment of acromegaly.What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients?Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutationsClinical manifestations and diagnosis of acromegalyMedical therapy of acromegalyPitfalls in the diagnosis of acromegaly.Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.Mononostril versus Binostril Endoscopic Transsphenoidal Approach for Pituitary Adenomas: A Systematic Review and Meta-Analysis.Sleep apnea in patients with acromegaly. Frequency, characterization and positive pressure titration.Insulin-like growth factor I levels and the diagnosis of adult growth hormone deficiency.The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly.Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegalyCorrelations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly.Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegalyTreatment strategies for acromegaly.The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy.Growth hormone and its disorders
P2860
Q21202912-8571B5FA-13D4-49CB-8E6C-B012BBD4F4F3Q26783670-9527D528-ADBD-4E19-A2F3-587706BF1D92Q26799418-8A1833C3-3523-4DF8-B9FB-71B6F4647CD2Q28730120-B3321BA6-764E-4DCB-B6E2-141554692020Q30408371-BB5802E5-6B34-457B-87F8-220571B66FFDQ30458356-3B18BFBC-8AA1-4E9E-B2C1-1AB6E214B449Q33569037-22D1B29C-9DBB-4922-B201-30A4A8D3F19BQ33725999-B8B3B226-860E-4A4C-A28D-1ADB1E67449AQ33739766-41F070E3-BB88-48F4-83F4-CFD6B6EEF1A0Q33772673-D80FD4A5-624B-4768-B98A-FCFBA217CF6FQ33794388-8345F830-AEA0-4305-8331-EE7AAD272F4CQ33817041-B2D7707B-FA9F-4CEB-849E-420CB3F1544FQ34050636-4BBE7FCC-4209-4271-85C1-9A0F2099289AQ34277844-83F27385-137E-4D17-AD5E-1AE1C664C303Q34362091-76AD2471-E737-4DFD-97E4-65A0D9C46095Q34815007-A2C72709-AE5D-4EC3-9E20-3C246466015AQ34840936-B379E748-D20C-4EE6-812A-4897D0D1BCC1Q34901376-466B7952-AF37-488C-81E6-A42E96921F71Q34981394-2F41FF26-EB0F-43F9-B8BD-BA117B1F9017Q34985044-2C491D4F-6D70-481D-9253-0764C4F30832Q35036288-8CBF7970-E838-4327-9DCC-0EB57F04D1AFQ35041716-C2C13801-CC6C-4996-BAFA-69856C7B8754Q35086868-663E0E70-2BF6-4BE4-AE90-B467A956C88BQ35125987-6702F30E-4F7A-4F00-B4F4-4353610E4D48Q35398197-F658EED6-62FA-4492-AD49-606D85576C25Q35676798-AEAC7B59-CC56-4E02-9B7D-46F3A665882EQ35810485-15D44430-23FC-46B7-9503-A017358F2BADQ35895856-363F2A32-A553-4C64-B8D1-8360568DF0C4Q35946611-EC63C9B4-A619-421B-9FDD-3563C7365E09Q35977997-860FE6E6-C027-45C1-9410-1461B36ECB06Q36001894-777396B9-F597-407C-87FC-2988FE84999AQ36067300-CE385A5E-CBAC-48AC-B97F-F6E3AB5A5E40Q36068042-0131A743-6EEF-492F-BE6C-4A07D8ED62C9Q36068074-2684BFC4-3845-4652-B24F-D630A38D7534Q36147952-64FC88F5-7364-429A-9629-947774561E57Q36196741-DE76FAE2-21D7-403E-81CE-B5C8FD22635AQ36236809-8CF45484-1E9B-4475-9B07-CE1D18E9A542Q36302865-A3E6BC00-D5B6-48B6-8E6D-ABCF814EA300Q36328066-CB7EDB7C-42CF-475D-A040-8FE7EF011A80Q36362200-CE7226D4-35EA-4B42-AEE5-29273A9D1700
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Criteria for cure of acromegaly: a consensus statement.
@ast
Criteria for cure of acromegaly: a consensus statement.
@en
type
label
Criteria for cure of acromegaly: a consensus statement.
@ast
Criteria for cure of acromegaly: a consensus statement.
@en
prefLabel
Criteria for cure of acromegaly: a consensus statement.
@ast
Criteria for cure of acromegaly: a consensus statement.
@en
P2093
P356
P1476
Criteria for cure of acromegaly: a consensus statement.
@en
P2093
Casanueva FF
Cavagnini F
Giustina A
Veldhuis J
Von Werder K
P304
P356
10.1210/JC.85.2.526
P407
P577
2000-02-01T00:00:00Z